DEXCOM INC (DC4.DE) Stock Fundamental Analysis
FRA:DC4 - Deutsche Boerse Ag - US2521311074 - Common Stock - Currency: EUR
Taking everything into account, DC4 scores 6 out of 10 in our fundamental rating. DC4 was compared to 53 industry peers in the Health Care Equipment & Supplies industry. DC4 scores excellent on profitability, but there are some minor concerns on its financial health. DC4 is growing strongly while it is still valued neutral. This is a good combination! This makes DC4 very considerable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year DC4 was profitable.
In the past year DC4 had a positive cash flow from operations.
Each year in the past 5 years DC4 has been profitable.
DC4 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.89%, DC4 belongs to the top of the industry, outperforming 84.91% of the companies in the same industry.
DC4 has a Return On Equity of 27.40%. This is amongst the best in the industry. DC4 outperforms 92.45% of its industry peers.
The Return On Invested Capital of DC4 (14.49%) is better than 96.23% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DC4 is above the industry average of 8.33%.
The 3 year average ROIC (11.25%) for DC4 is below the current ROIC(14.49%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.89% | ||
| ROE | 27.4% | ||
| ROIC | 14.49% |
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
1.3 Margins
The Profit Margin of DC4 (14.29%) is better than 83.02% of its industry peers.
In the last couple of years the Profit Margin of DC4 has grown nicely.
DC4 has a Operating Margin of 16.20%. This is amongst the best in the industry. DC4 outperforms 81.13% of its industry peers.
In the last couple of years the Operating Margin of DC4 has grown nicely.
DC4's Gross Margin of 61.78% is in line compared to the rest of the industry. DC4 outperforms 54.72% of its industry peers.
DC4's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.2% | ||
| PM (TTM) | 14.29% | ||
| GM | 61.78% |
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so DC4 is still creating some value.
Compared to 1 year ago, DC4 has more shares outstanding
The number of shares outstanding for DC4 has been increased compared to 5 years ago.
The debt/assets ratio for DC4 has been reduced compared to a year ago.
2.2 Solvency
DC4 has an Altman-Z score of 5.38. This indicates that DC4 is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of DC4 (5.38) is better than 90.57% of its industry peers.
The Debt to FCF ratio of DC4 is 3.96, which is a good value as it means it would take DC4, 3.96 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of DC4 (3.96) is better than 73.58% of its industry peers.
DC4 has a Debt/Equity ratio of 0.62. This is a neutral value indicating DC4 is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.62, DC4 is not doing good in the industry: 64.15% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.62 | ||
| Debt/FCF | 3.96 | ||
| Altman-Z | 5.38 |
ROIC/WACC1.67
WACC8.66%
2.3 Liquidity
A Current Ratio of 1.47 indicates that DC4 should not have too much problems paying its short term obligations.
DC4's Current ratio of 1.47 is in line compared to the rest of the industry. DC4 outperforms 47.17% of its industry peers.
A Quick Ratio of 1.28 indicates that DC4 should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.28, DC4 is in the better half of the industry, outperforming 66.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.28 |
3. Growth
3.1 Past
DC4 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.27%, which is quite good.
The Earnings Per Share has been growing by 29.25% on average over the past years. This is a very strong growth
The Revenue has grown by 11.34% in the past year. This is quite good.
The Revenue has been growing by 22.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)9.27%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%-10%
Revenue 1Y (TTM)11.34%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%7.64%
3.2 Future
The Earnings Per Share is expected to grow by 20.38% on average over the next years. This is a very strong growth
DC4 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.62% yearly.
EPS Next Y24.84%
EPS Next 2Y23.78%
EPS Next 3Y23.37%
EPS Next 5Y20.38%
Revenue Next Year14.47%
Revenue Next 2Y14.96%
Revenue Next 3Y15.03%
Revenue Next 5Y14.62%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 43.32, the valuation of DC4 can be described as expensive.
The rest of the industry has a similar Price/Earnings ratio as DC4.
When comparing the Price/Earnings ratio of DC4 to the average of the S&P500 Index (28.79), we can say DC4 is valued expensively.
Based on the Price/Forward Earnings ratio of 34.64, the valuation of DC4 can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of DC4 is on the same level as its industry peers.
The average S&P500 Price/Forward Earnings ratio is at 21.38. DC4 is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.32 | ||
| Fwd PE | 34.64 |
4.2 Price Multiples
DC4's Enterprise Value to EBITDA is on the same level as the industry average.
DC4's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. DC4 is cheaper than 64.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 44.36 | ||
| EV/EBITDA | 29.75 |
4.3 Compensation for Growth
DC4's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
DC4 has an outstanding profitability rating, which may justify a higher PE ratio.
DC4's earnings are expected to grow with 23.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.74
PEG (5Y)1.48
EPS Next 2Y23.78%
EPS Next 3Y23.37%
5. Dividend
5.1 Amount
DC4 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:DC4 (4/25/2025, 7:00:00 PM)
62.82
+1.16 (+1.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners96.25%
Inst Owner ChangeN/A
Ins Owners0.35%
Ins Owner ChangeN/A
Market Cap24.63B
Analysts86.25
Price Target90.13 (43.47%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.07%
Min EPS beat(2)-11.66%
Max EPS beat(2)1.51%
EPS beat(4)3
Avg EPS beat(4)3.82%
Min EPS beat(4)-11.66%
Max EPS beat(4)16.17%
EPS beat(8)7
Avg EPS beat(8)16.74%
EPS beat(12)9
Avg EPS beat(12)9.83%
EPS beat(16)12
Avg EPS beat(16)13.09%
Revenue beat(2)0
Avg Revenue beat(2)-1.43%
Min Revenue beat(2)-1.66%
Max Revenue beat(2)-1.2%
Revenue beat(4)0
Avg Revenue beat(4)-2.13%
Min Revenue beat(4)-4.99%
Max Revenue beat(4)-0.69%
Revenue beat(8)3
Avg Revenue beat(8)-0.57%
Revenue beat(12)4
Avg Revenue beat(12)-0.74%
Revenue beat(16)7
Avg Revenue beat(16)0.05%
PT rev (1m)-9.28%
PT rev (3m)-7.98%
EPS NQ rev (1m)0.83%
EPS NQ rev (3m)-16.54%
EPS NY rev (1m)0.17%
EPS NY rev (3m)-0.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.24%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.32 | ||
| Fwd PE | 34.64 | ||
| P/S | 6.94 | ||
| P/FCF | 44.36 | ||
| P/OCF | 28.27 | ||
| P/B | 13.3 | ||
| P/tB | 14.15 | ||
| EV/EBITDA | 29.75 |
EPS(TTM)1.45
EY2.31%
EPS(NY)1.81
Fwd EY2.89%
FCF(TTM)1.42
FCFY2.25%
OCF(TTM)2.22
OCFY3.54%
SpS9.06
BVpS4.72
TBVpS4.44
PEG (NY)1.74
PEG (5Y)1.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.89% | ||
| ROE | 27.4% | ||
| ROCE | 18.4% | ||
| ROIC | 14.49% | ||
| ROICexc | 52.88% | ||
| ROICexgc | 60.76% | ||
| OM | 16.2% | ||
| PM (TTM) | 14.29% | ||
| GM | 61.78% | ||
| FCFM | 15.64% |
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
ROICexc(3y)35.45%
ROICexc(5y)29.66%
ROICexgc(3y)40.94%
ROICexgc(5y)33.19%
ROCE(3y)14.28%
ROCE(5y)11.73%
ROICexcg growth 3Y55.18%
ROICexcg growth 5Y18.96%
ROICexc growth 3Y50.14%
ROICexc growth 5Y16.58%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
F-Score7
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.62 | ||
| Debt/FCF | 3.96 | ||
| Debt/EBITDA | 1.49 | ||
| Cap/Depr | 164.81% | ||
| Cap/Sales | 8.9% | ||
| Interest Coverage | 57.32 | ||
| Cash Conversion | 113.58% | ||
| Profit Quality | 109.46% | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.28 | ||
| Altman-Z | 5.38 |
F-Score7
WACC8.66%
ROIC/WACC1.67
Cap/Depr(3y)175.34%
Cap/Depr(5y)240.83%
Cap/Sales(3y)9.32%
Cap/Sales(5y)10.84%
Profit Quality(3y)97.76%
Profit Quality(5y)73.64%
High Growth Momentum
Growth
EPS 1Y (TTM)9.27%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%-10%
EPS Next Y24.84%
EPS Next 2Y23.78%
EPS Next 3Y23.37%
EPS Next 5Y20.38%
Revenue 1Y (TTM)11.34%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%7.64%
Revenue Next Year14.47%
Revenue Next 2Y14.96%
Revenue Next 3Y15.03%
Revenue Next 5Y14.62%
EBIT growth 1Y6.38%
EBIT growth 3Y30.52%
EBIT growth 5Y33.11%
EBIT Next Year76.73%
EBIT Next 3Y37.42%
EBIT Next 5Y29.37%
FCF growth 1Y23.21%
FCF growth 3Y127.88%
FCF growth 5Y36.21%
OCF growth 1Y32.2%
OCF growth 3Y30.77%
OCF growth 5Y25.76%